Ploxal-S

Quick links to important sections

Ploxal-S

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ploxal-S

Quick Facts

Property Description
Active ingredient Oxaliplatin (INN)
Form Concentrate or powder for Intravenous (IV) Infusion
Pharmacological class Antineoplastic Agent (Platinum Compound)
General Purpose Interferes with the replication of rapidly dividing cells
Origin Synthetic, Third-Generation Platinum Analog

What Type of Medicine is Ploxal-S? (Identity, Class, and Composition)

Ploxal-S is the brand name for a prescription-only medication whose active ingredient is Oxaliplatin (INN). This substance is a synthetic compound and a platinum-containing antineoplastic agent. This categorization places the medicine within the broader class of alkylating agents, structurally defined by the inclusion of a central platinum atom. Unlike earlier platinum compounds, such as Cisplatin or Carboplatin, Ploxal-S provides a third-generation platinum analog that is clinically recognized for its distinct chemical configuration, specifically the DACH-platinum species. This unique structure is associated with differentiated biological activity. Ploxal-S is a single-active ingredient product intended for specific therapeutic protocols.

Ploxal-S Drug Form and General Purpose

Ploxal-S is supplied exclusively as a sterile preparation, either a concentrate for solution for intravenous infusion or a lyophilized powder intended for reconstitution. This form necessitates delivery via the intravenous (IV) route of administration after dilution, ensuring precise systemic availability. The general purpose of this cytotoxic agent is to interfere directly with the growth and reproduction of rapidly dividing cells in the body. By causing irreparable DNA damage and inhibiting genetic synthesis—a basic mechanism associated with its class—Ploxal-S achieves its therapeutic goal of helping to slow the proliferation, reduce the size, and limit the spread of targeted cell populations.

Regulatory References

  1. MedlinePlus

What side effects are possible with Ploxal-S?

Possible Side Effects and Safety Information

The safety profile of Ploxal-S is classified based on the frequency and the System-Organ Class (SOC) affected, as documented in official regulatory sources. The most significant and common safety concern is peripheral sensory neuropathy, which is classified as very common. This neurological effect presents in two patterns: an acute form that is often transient and may be triggered by cold exposure, and a persistent form that is associated with cumulative dose and may lead to long-term functional changes.

Very Common adverse reactions also include disorders of the Blood and lymphatic system, primarily myelosuppression (neutropenia, thrombocytopenia, and anemia), and Gastrointestinal disorders such as nausea, vomiting, and diarrhea. General systemic effects like fatigue and fever are also frequently noted. Less frequent, or rare, but serious adverse reactions documented in labeling include severe hypersensitivity (anaphylaxis) and Reversible Posterior Leukoencephalopathy Syndrome (RPLS).

Safety Domain Key Safety Considerations
Dose-Limiting Toxicity Peripheral sensory neuropathy (acute and persistent forms).
Serious Adverse Reactions Severe myelosuppression and Grade 3/4 hypersensitivity reactions.
Population-Specific Notes Increased risk of Grade 3/4 toxicity (diarrhea and neutropenia) documented for older adults (ge70 years).

Regulatory documents also define specific limitations for initiating treatment. The medicine is contraindicated in patients with a pre-existing peripheral sensory neuropathy of Grade 2 or greater or with severe myelosuppression before the first cycle of therapy.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Ploxal-S (Oxaliplatin) is officially documented to result from an exacerbation of the drug’s known toxicities, which can lead to severe and potentially life-threatening outcomes.


Documented Overdose Manifestations

System Documented Effects
Neurological Severe sensory neuropathy, agitation, lethargy, seizures, and coma.
Gastrointestinal Profuse vomiting, diarrhea, abdominal pain, and stomatitis.
Cardiovascular/Respiratory Slowed heartbeat, chest pain, and respiratory failure.

Severe Outcomes and Emergency Action

Overdosage is associated with severe complications, including Grade 4 thrombocytopenia and anemia (severe myelosuppression), as well as renal failure and disseminated intravascular coagulation (DIC). The regulatory data notes that dose-related factors have been reported following single infusions up to 825 mg. No population-specific differences in overdose severity are explicitly documented in official labeling.

Regulatory guidance mandates seeking immediate emergency medical attention if the individual exhibits acute, life-threatening symptoms such as collapse, seizure, trouble breathing, or unconsciousness. Management procedures, as described in official labeling, require close patient monitoring and the administration of appropriate supportive treatment. The official documentation explicitly states that no specific antidote is known for Ploxal-S overdosage.

Therapeutic Uses of Ploxal-S

What Ploxal-S Treats: Main Uses and Benefits

Ploxal-S is commonly used in treating various cancers, generally applied in clinical settings that involve aggressive cell proliferation and a heightened risk of systemic disease progression. This agent is primarily used in combination with other medications to help manage challenging symptomatic conditions.

The medicine is commonly used across conditions presenting with acute episodes, including advanced or metastatic colorectal cancer, Stage III colon cancer following surgery, and select cases of refractory or relapsed solid tumors.

Therapeutic Benefits and Clinical Context

This medication is applied across domains where additional symptomatic support is needed. In patients with widespread disease, its main benefit is the ability to help slow tumor growth, reduce the overall tumor size, and limit the spread of the malignancy, which contributes to easing the overall symptom load.

In the adjuvant setting (after tumor removal), Ploxal-S offers therapeutic support by reducing the risk that the cancer may return, and may assist with maintaining a sense of stability during long-term health management. It is often used during phases when symptoms become more noticeable due to active or residual disease.

“This medication may support a treatment strategy aimed at managing aggressive disease and the overall symptom burden.”


Quick Fact: Primary Uses Description
Primary Indication Colorectal cancer (advanced/metastatic and Stage III adjuvant)
Key Benefit Contributes to easing the overall symptom load associated with aggressive cellular activity
Clinical Scenarios Post-surgical management and initial therapy for widely spread disease

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Ploxal-S (Oxaliplatin) is authorized for use primarily in adult patients receiving treatment for advanced or Stage III colorectal cancer. Eligibility is determined by clear regulatory criteria regarding age, physiological status, and pre-existing conditions.

Contraindicated Populations

Official labeling mandates that Ploxal-S must not be used in the following groups:

  • Patients with a known hypersensitivity or allergy to oxaliplatin or other platinum-containing medicines.
  • Women who are pregnant or breast-feeding (use is strictly contraindicated).
  • Patients presenting with a pre-existing functional peripheral sensory neuropathy.
  • Patients with severe renal impairment (creatinine clearance < 30 mL/min) are either contraindicated (international labels) or require a mandatory dose reduction (FDA).

Age and Conditional Use

Population Official Regulatory Status
Pediatric Patients Safety and effectiveness are not established; authorized for adults only.
Geriatric Patients Generally eligible; requires monitoring for events like dehydration.

Patients with mild to moderate renal impairment are eligible but must be closely monitored. Furthermore, therapy must be delayed for patients with inadequate baseline blood counts (severe myelosuppression) until specified regulatory levels are met.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents define the interaction profile of Ploxal-S based on formal prohibitions, the management of systemic exposure, and the avoidance of additive toxicities.

Interaction Category Official Regulatory Statement
Formal Contraindications Live Vaccines are contraindicated due to the risk of pharmacodynamic antagonism. Co-administration with Dronedarone, Thioridazine, and Pimozide is strictly prohibited due to the documented risk of additive QTc interval prolongation.
Timing Rule The administration of 5-Fluorouracil (5-FU) must be sequential and is prohibited from being concurrent in the same line. Regulatory constraints specify that Ploxal-S must always be administered before 5-FU in the treatment regimen to manage potential exposure changes.
Exposure and Toxicity Risk Clearance of the platinum species, which occurs primarily through the kidneys, may be decreased when co-administered with potentially nephrotoxic compounds. This reduced clearance leads to increased systemic exposure, a pharmacokinetic risk also documented to occur in patients with severe renal impairment. The drug label advises avoidance of other QT-prolonging agents and medicines with specific neurological toxicity due to the risk of additive pharmacodynamic effects. Notably, no CYP450-mediated drug-drug interactions are anticipated.

This structure reflects the regulatory classification of mandatory restrictions and co-administration conditions necessary to manage systemic and additive interaction risks as established by authoritative government agencies.

Mechanism of Action

Mechanism 1: Inducing Cell Death via DNA Crosslinking

The primary mechanism involves the drug's active metabolites covalently binding to and crosslinking nuclear DNA primarily at guanine residues. This irreparable damage physically inhibits essential cellular functions like replication and transcription, overwhelming the cell's repair mechanisms and leading to the physiological consequence of apoptosis (programmed cell death).

Mechanism 2: Modulation of Peripheral Nerve Ion Channels

Separate from its nuclear action, the drug and its byproducts exert an off-target effect by directly interacting with voltage-gated sodium ion channels on peripheral sensory nerves. This biophysical modulation increases neuronal excitability, resulting in an immediate and transient spike in nerve signal activity that defines this distinct physiological profile.

️ Mechanism 3: Limitations by DNA Repair

The cytotoxic effect of the mechanism is physiologically constrained by the cell's inherent defense systems, especially the Nucleotide Excision Repair (NER) pathway. Cells with highly active repair mechanisms, such as those overexpressing ERCC1, can excise the platinum-DNA crosslinks before apoptosis is triggered, thereby reducing the total burden of DNA adducts and preventing the cascade to apoptosis.

Dosage and Administration Information

How Ploxal-S is Used

Ploxal-S (Oxaliplatin) is a prescription-only medication whose use is governed by established protocols. The medicine is administered only in a specialized clinical setting under the supervision of a physician experienced in cancer chemotherapy.


Administration and Dosage Standards

Usage Parameter Standard Parameters
Route and Setting Exclusively via Intravenous (IV) Infusion in a clinical environment.
Standard Dose The initial recommended dose is 85 mg/m^2 (milligrams per square meter of body surface area).
Dosing Schedule Administered as part of a combination regimen that repeats every two weeks (a 14-day cycle).
Infusion Duration Typically given over 120 minutes (2 hours), though it may be prolonged up to 6 hours.

Preparation and Procedural Rules

The correct preparation and handling of Ploxal-S are strictly followed to ensure proper use:

  • Dilution: The concentrate must be diluted with 5% Dextrose Injection (D5W), using a volume between 250 and 500 mL.
  • Chemical Restriction: It is forbidden to dilute Ploxal-S with sodium chloride or other chloride-containing solutions.
  • Sequence: The Ploxal-S infusion must always precede the administration of the other fluoropyrimidine agents in the combination regimen.

Use in Specific Populations

Clinical guidelines detail high-level dosage adjustments for specific patient groups. For individuals with severe renal impairment (creatinine clearance less than 30 mL/min), the initial recommended dose is reduced to 65 mg/m^2. For patients receiving adjuvant therapy, treatment is typically continued for a maximum of 12 cycles (6 months), while treatment for advanced disease continues until disease progression.

Recent Clinical Evidence

Evidence for Use in Advanced or Metastatic Colorectal Cancer

Research for Ploxal-S in widely spread (advanced or metastatic) colorectal cancer includes large-scale Randomized Controlled Trials (RCTs). These studies compared regimens containing Ploxal-S against other treatments, examining outcomes like Progression-Free Survival (PFS), Overall Survival (OS), and Objective Tumor Response (tumor size reduction). Research describes settings for both initial therapy and managing disease that had progressed.


Evidence for Use in Adjuvant Stage III Colon Cancer

Adjuvant trials evaluated Ploxal-S following surgery for Stage III colon cancer. These studies monitored the outcome of Disease-Free Survival (DFS), which research observed as the period patients remained without recurrence, contributing to understanding the long-term context of the condition.


Long-Term Follow-up and Durability of Study Outcomes

Major clinical trials included extensive long-term follow-up, with data available ranging from three years up to ten years in some pivotal studies. These studies explored the durability of observed patterns related to recurrence and survival. However, long-term effects are not fully established for all subgroups, and certain chronic changes are not well characterized.


Research in Special Patient Populations

Research has explored how Ploxal-S was evaluated in older adults through dedicated subgroup analyses and observational studies. While findings describe patterns across many adult age ranges, certain specific cohorts (e.g., the very oldest patients) had mixed or inconsistent findings for long-term survival measures reported in some studies.


What is Still Uncertain in the Research Landscape

While the evidence base has been reviewed for regulatory authorization, evidence quality varies across studies, and generalizability constraints exist because RCT populations often represent a healthier, younger patient cohort. Certainty remains low regarding the use of Ploxal-S when it is re-evaluated after a disease-free interval, especially in late-line treatment settings.

Frequently Asked Questions (FAQ)

Common questions about Ploxal-S (FAQ)

Q: Is Ploxal-S a steroid or an antibiotic?

A: Official product information states that Ploxal-S is an Antineoplastic Agent (a cancer drug) belonging to the class of Platinum Compounds. This classification means it works by interfering with cell growth. It is not classified as an antibiotic, which fights bacteria, or a steroid.


Q: Can Ploxal-S cause mood changes or anxiety?

A: Official information on adverse reactions reports of mood changes as an adverse reaction in connection with the medicine. While the incidence rate is not always known, this is documented as a possible effect.


Q: If I miss a dose of Ploxal-S, what happens?

A: Ploxal-S is administered in a specialized clinical setting according to a strict schedule. Regulatory-based patient information emphasizes that it is important not to miss a scheduled treatment. If an appointment is missed, it is important to consult the healthcare team for guidance on rescheduling as soon as possible.


Q: Can people with liver issues take Ploxal-S?

A: Studies and official documents indicate that Oxaliplatin may cause or contribute to hepatotoxicity, which is liver damage. Because of this, liver function tests are routinely monitored during treatment. Patients with pre-existing liver issues may be eligible, but regulatory documents recommend close monitoring of liver function.


Q: Does Ploxal-S affect birth control pills?

A: Official product information describes the medicine as genotoxic, meaning it has the potential to damage genetic material. Because of the risk of fetal harm, females and males of reproductive potential should be informed of the need for effective contraception during and for a specified time period after treatment.


Q: Do I need to avoid certain foods when using Ploxal-S?

A: Official regulatory documents provide specific advice regarding temperature exposure. Patients are advised to avoid cold drinks and cold objects, as these can potentially trigger or worsen the acute form of sensory neuropathy.


Q: How long does Ploxal-S stay in your system after stopping it?

A: Pharmacological data indicates that the terminal elimination phase of the platinum component (mostly inactive conjugates) in the blood can be long. This elimination process is described as taking up to 392 hours, or about 16 days.


Q: Does Ploxal-S require a special diet or fluid intake?

A: Regulatory advice focuses on mitigating side effects by recommending the avoidance of cold exposure, which includes cold foods and drinks. For managing potential gastrointestinal side effects like a sore mouth, patient information suggests drinking plenty of fluids and avoiding foods or drinks that could cause irritation.


Q: Can Ploxal-S affect the results of lab tests?

A: Yes, Ploxal-S is commonly associated with changes in certain blood parameters documented in clinical trials. It can cause a decrease in blood counts (myelosuppression), including neutropenia, thrombocytopenia, and anemia. It may also lead to an increase in liver enzyme results, such as alkaline phosphatase and transaminases.


Q: Does Ploxal-S have a known generic equivalent?

A: Yes, the active ingredient in Ploxal-S is Oxaliplatin. According to regulatory records and DailyMed listings, this active ingredient is available as a generic injection.


Q: Is Ploxal-S known to cause weight gain?

A: Studies have examined the effect of the medicine on weight. Weight increase (weight gain) has been reported as an adverse reaction in clinical trial data, with an incidence rate of 10% among patients.


Q: Can men use Ploxal-S if they are trying to conceive?

A: Official product information states that the medicine has genotoxic effects. Regulatory information states that males with female partners of reproductive potential should be informed of the need for effective contraception for a period of 6 months after the final dose.


Q: Is it normal to have a slight headache when starting Ploxal-S?

A: Clinical trial data reports that headache is a known adverse reaction associated with the medicine. Official data indicates this occurred with an incidence rate of 7% in patients.


Q: What is the purpose of the black box warning (if one exists) for Ploxal-S?

A: The FDA Boxed Warning is the most serious advisory from the agency. For Ploxal-S, this warning focuses on the risk of Serious and Fatal Hypersensitivity Reactions, which can include anaphylaxis (a severe, life-threatening allergic reaction).


Q: How does alcohol consumption relate to taking Ploxal-S?

A: Regulatory-based patient information states that alcohol use during treatment may cause side effects to become worse.


Q: Is Ploxal-S considered a 'new' drug, or has it been around for a while?

A: Official documents classify Ploxal-S as a Third-Generation Platinum Analog. This means it is a more recently developed compound in the platinum-based chemotherapy drug class, following earlier drugs like Cisplatin and Carboplatin.


Q: Can Ploxal-S cause changes to vision or hearing?

A: Official patient information reports that the drug is associated with certain sensory changes. This includes reports of vision problems such as blurriness or transient vision loss, and, less commonly, reports of deafness as an auditory side effect.


Q: Can Ploxal-S be taken at the same time as antacids?

A: The drug label advises against coadministration with other medicinal products known to cause nephrotoxicity (kidney damage). This is a general restriction that may apply to certain antacids. Coadministration must be evaluated on a case-by-case basis before starting treatment.


Q: Can taking Ploxal-S affect my ability to drive or operate machinery?

A: Official patient information states that Ploxal-S can cause side effects like dizziness, vision problems, or vision loss. If a patient experiences these symptoms, they should refrain from driving or operating machinery.


Q: What if I experience unusual skin changes while taking Ploxal-S?

A: Documented adverse skin reactions include rash, hives, pruritus (itching), and erythema (redness). The medicine is also associated with alopecia (hair loss). Any unusual or severe skin changes should be reported to the treatment team.


Q: Can I take Ploxal-S if I have a history of seizures?

A: Seizures are a documented symptom of a rare but serious adverse reaction called Posterior Reversible Encephalopathy Syndrome (PRES). For this reason, new or worsening seizures must be reported to the treatment team immediately due to the seriousness of this event.


Q: How does Ploxal-S affect people with diabetes?

A: Studies examining chemotherapy drugs indicate that they may have an impact on blood sugar control. Patients with pre-existing diabetes may find that their condition is worsened or requires adjustments to their management plan while on this medication.

How should Ploxal-S be stored and disposed of?

How to Store and Dispose of Ploxal-S?

Ploxal-S (Oxaliplatin) must be handled and stored according to specific regulatory requirements to maintain product stability and ensure safe disposal of this cytotoxic agent.

Storage Requirements

Unopened vials must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must remain in its original container until preparation. Once diluted, the solution must not be frozen and is stable for up to 24 hours under refrigeration (2 C to 8 C) or 6 hours at room temperature.

Disposal and Safety

All vials and supplies must be kept out of the sight and reach of children. Unused or expired Ploxal-S, along with all contaminated materials, must be treated as hazardous medicinal waste and disposed of according to local regulatory protocols for cytotoxic drugs. The medicine must not be thrown into household trash or poured into wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ploxal-S found in:

A-Z Index: